---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-025458"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T13:54:07.281195+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pieris Q3 net loss $9.7M ($0.13/sh); cash at $69.8M, funded into Q2 2024

## Summary
- Net loss of $9.7M ($0.13 per share) vs $16.5M ($0.24) in Q3 2021.
- Cash and investments $69.8M at Sept 30, down from $117.8M at Dec 31, 2021; company expects funding into Q2 2024.
- R&D expense $13.6M (down from $18.9M); G&A $3.9M (down from $4.1M).
- Elarekibep Phase 2a asthma study enrollment continues; topline FEV1 results expected by Q3 2023.
- PRS-220 Phase 1 first subject dosed; IND accepted for SGN-BB228; PRS-342 Phase 1 start within 6 months.

## SEC filing metadata
- accession: 0001437749-22-025458
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000143774922025458/0001437749-22-025458-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000143774922025458/pirs20220831_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-025458
- JSON: https://secwatch.observer/filing/0001437749-22-025458.json
- Plain text: https://secwatch.observer/filing/0001437749-22-025458.txt

## Key facts
- Earnings Releases
  PALVELLA THERAPEUTICS, INC. reported financial results for the third quarter of 2022 ended September 30, 2022.
  - Period: the third quarter of 2022 ended September 30, 2022
  - Result: reported results
  source text: On November 2, 2022, Pieris Pharmaceuticals, Inc. (the “Company”) issued a press release announcing certain financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583648/000143774922025458/0001437749-22-025458-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.